India is likely to approve Emergency Use Authorisation for the Merck drug Molnupiravir in a few days time. Molnupiravir is an oral drug designed to block the replication of various RNA viruses, including the SARS-CoV-2 virus. The medicine is meant for adults who are at risk for progressing to severe COVID-19 or hospitalization. The medicine can be taken at home.
Dr Ram Vishwakarma, Chairman of the Covid Strategy Group, CSIR calling the drugs the "final nail in the coffin of the virus by science", said, "I think Molnupiravir will be already available to us. Five companies are sitting with the drug manufacturer... I think any day we will have approval of Molnupiravir"
Five Indian pharmaceutical companies had partnered to conduct a clinical trial of Merck (MSD)’s experimental antiviral candidate Molnupiravir to treat mild Covid-19 in an outpatient setting. The partners are Cipla, Dr Reddy’s Laboratories, Sun Pharmaceutical Industries and Torrent Pharmaceuticals.
Molnupiravir works by disrupting the virus’s reproduction. Once the virus gets inside the body’s cells, it replicates its genome, which is made not of DNA but RNA (ribonucleic acid). These replicated genomes are then formed into complete virus particles which burst out of the cell and continue to spread around the body. However, the molecules of molnupiravir are absorbed by virus-infected cells, where they are converted into a defective version of the building blocks of RNA. So, when the virus tries to replicate, the resulting virus particles have defective genetic material and can no longer reproduce. This means that the viral load should remain low, which reduces the risk of serious disease.
In India, it might initially cost "2000 to 3000 or 4000 rupees per cycle of treatment, then it will come down to 500 to 600 or 1,000 rupees.
🕑 19 May,22 7:03p.m.
Defence Ministry developing centralised payment system for the Armed Forces
🕑 19 May,22 9:32a.m.
Defence Ministry sets May 25 as deadline to submit life certificate
🕑 18 May,22 8:25p.m.
60 central public sector enterprises identified for privatization or closure
🕑 18 May,22 12:07p.m.
Govt fixes 4% reservation in promotion for Persons with Benchmark Disabilities
🕑 14 May,22 9:02a.m.
AXIS, HDFC, ICICI, & Kotak Mahindra uthorised for railway pension disbursement
🕑 14 May,22 8:55a.m.
CGEGIS - Tables of benefits for the savings fund for Q! FY22-23
🕑 11 May,22 9:57a.m.
Railways constitutes Cadre Restructuring Committee | Find the members
🕑 10 May,22 10:23p.m.
Departmental proceedings needed even for termination of temporary staff; HC
🕑 04 May,22 7:55p.m.
Amazon Summer Sale Offers: Up to 80% off + Savings
🕑 30 Apr,22 11:55p.m.
March AI CPI-IW up sharp 1 by point. Expected DA from July 2022 is 37%
🕑 30 Apr,22 11:04a.m.
Understanding Aykroyd formula, which the 8th Pay Commission might depend
🕑 26 Apr,22 3:28p.m.
All persons who caught Covid at risk of this dangerous side-effect
🕑 25 Apr,22 9:43p.m.
Ola to launch self driving electric car in the range of ₹ 10 Lakhs in two years
🕑 23 Apr,22 11:13p.m.
RBI makes credit card more friendly & safe. 10 points on new rules
🕑 23 Apr,22 11:17a.m.
Fitment factors recommended by pay commissions over the years
🕑 22 Apr,22 12:48a.m.
IT benefit on HRA can be claimed by paying rent to wife rules Delhi Tribunal
🕑 19 Apr,22 9:29p.m.
Investing in your child's name can help you save tax
🕑 17 Apr,22 12:07p.m.
Do not file income tax returns for AY 2022-23 before June 1, 2022